SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sobin L, Gospodarowicz M, Wittekind C, eds. International Union Against Cancer: TNM Classification of Malignant Tumors. 7th ed. New York: John Wiley & Sons, Inc.; 2009.
  • 2
    Rusch VW, Crowley J, Giroux DJ, et al. for the International Staging Committee, Cancer Res. and Biostatistics, Observers to the Committee, and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2007; 2: 603-612.
  • 3
    Maggi G, Casadio C, Mancuso M, Oliaro A, Cianci R, Ruffini E. Resection and radical lymphadenectomy for lung cancer: prognostic significance of lymphatic metastases. Int Surg. 1990; 75: 17-21.
  • 4
    Martini N, Burt ME, Bains MS, McCormack PM, Rusch VW, Ginsberg RJ. Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg. 1992; 54: 460-466.
  • 5
    Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes. J Thorac Cardiovasc Surg. 1994; 107: 1398-1402.
  • 6
    van Velzen E, Snijder RJ, Brutel de la Riviere A, Elbers HJ, van den Bosch JM. Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases. Chest. 1996; 110: 1469-1473.
  • 7
    van Velzen E, Snijder RJ, Brutel de la Riviere A, Elbers HR, van den Bosch JM. Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. Ann Thorac Surg. 1997; 63: 1436-1440.
  • 8
    van Velzen E, de la Riviere AB, Elbers HJ, Lammers JW, van den Bosch JM. Type of lymph node involvement and survival in pathologic N1 stage III non-small cell lung carcinoma. Ann Thorac Surg. 1999; 67: 903-907.
  • 9
    Sawyer TE, Bonner JA, Gould PM, et al. Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma. Ann Thorac Surg. 1999; 68: 1171-1176.
  • 10
    Riquet M, Manac'h D, Le Pimpec-Barthes F, Dujon A, Chehab A. Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung. Ann Thorac Surg. 1999; 67: 1572-1576.
  • 11
    Yoshino I, Nakanishi R, Osaki T, et al. Unfavorable prognosis of patients with stage II non-small cell lung cancer associated with macroscopic nodal metastases. Chest. 1999; 116: 144-149.
  • 12
    Asamura H, Suzuki K, Kondo H, Tsuchiya R. Where is the boundary between N1 and N2 stations in lung cancer? Ann Thorac Surg. 2000; 70: 1839-1845.
  • 13
    Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p-) T1–2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg. 2001; 19: 555-561.
  • 14
    Marra A, Hillejan L, Zaboura G, Fujimoto T, Greschuchna D, Stamatis G. Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg. 2003; 125: 543-553.
  • 15
    Osaki T, Nagashima A, Yoshimatsu T, Tashima Y, Yasumoto K. Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer. 2004; 43: 151-157.
  • 16
    Sayar A, Turna A, Kilicgun A, Solak O, Urer N, Gurses A. Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung. Eur J Cardiothorac Surg. 2004; 25: 434-438.
  • 17
    Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E. Prognostic variability among nonsmall cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications. Cancer. 2006; 107: 793-798.
  • 18
    Nakagawa T, Okumura N, Kokado Y, Miyoshi K, Matsuoka T, Kameyama K. Retrospective study of patients with pathologic N1-stage II non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2007; 6: 474-478.
  • 19
    Cerfolio RJ, Bryant AS. Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer. Ann Thorac Surg. 2007; 84: 182-190.
  • 20
    Demir A, Turna A, Kocaturk C, et al. Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer. Ann Thorac Surg. 2009; 87: 1014-1022.
  • 21
    Jonnalagadda S, Smith C, Mhango G, Wisnivesky JP. The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer. Chest. 2011; 140: 433-440.
  • 22
    Jonnalagadda S, Arcinega J, Smith C, Wisnivesky JP. Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer [published online ahead of print March 30, 2011]. Cancer. 2011.
  • 23
    Rzyman W, Hagen OM, Dziadziuszko R, et al. Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients. Ann Thorac Surg. 2006; 82: 237-242.
  • 24
    Liptay MJ, D'Amico TA, Nwogu C, et al; on behalf of the Thoracic Surgery Subcommittee of Cancer and Leukemia Group B. Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009; 4: 198-202.
  • 25
    Kim S, Kim HK, Kang DY, Jeong JM, Choi YH. Intra-operative sentinel lymph node identification using a novel receptor-binding agent (technetium-99m neomannosyl human serum albumin, 99mTc-MSA) in stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2010; 37: 1450-1456.
  • 26
    Nomori H, Kohno M, Izumi Y, Ohtsuka T, Asakura K, Nakayama T. Sentinel nodes in lung cancer: review of our 10-year experience. Surg Today. 2011; 41: 889-895.